NY-NFL/OVERTIER
The National Football League (NFL) and OverTier, a Bruin Sports Capital (Bruin) company, today announced an expansion of their partnership for OverTier to operate NFL Game Pass, the league’s premium subscription OTT service. Since 2017, OverTier held the rights to operate NFL Game Pass in Europe. The new agreement now brings the service to a combined 181 countries and territories worldwide including Australia, Brazil, Hong Kong, India, Israel, Japan, Mexico, and South Korea.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191007005597/en/
NFL Game Pass offers all live NFL Games, NFL Red Zone, NFL Network and a deep catalog of original programming, documentaries, series and specials from the award-winning NFL Films. It is available across 11 platforms through connected TV, games consoles, web and mobile.
“We are excited to expand our partnership with OverTier to bring the NFL directly to fans around the world on their favorite viewing platforms with NFL Game Pass,” said Chris Halpin, NFL Chief Strategy & Growth Officer. “OverTier has a proven track record of innovation in Europe, and we look forward to unlocking significant potential across other markets.”
“We are delighted with the progress we’ve made with our NFL partners. Together we have built a detailed understanding of how to cultivate and super serve fans throughout Europe and have turned that into meaningful business gain with great long-term potential,” said Sam Jones, OverTier CEO. “We look forward to applying our unique model to these expanded global markets and with the league develop more fans and opportunities worldwide.”
Over the past two seasons, a suite of user-led product innovations delivered a more personalized viewing experience to more fans across more platforms and services in Europe than ever. There has been a meaningful growth in subscriptions to NFL Game Pass in Europe, total NFL GPE regular-season viewership was up 46% year-on-year (’17-’18), with average minutes per viewer increasing by 20% to 62 hours. Live Super Bowl viewership was up 33% year-on-year and playoff viewership up 30%. Mobile viewership increased by 26% year-on-year, while the total number of devices subscribers used to watch GPE increased by 33% (a GPE subscription allows up to five concurrent streams). Eight hundred million hours of content was streamed, representing over 91,000 years of content. The Android app was the highest rated of all sports subscription OTT services globally.
OverTier was created by Bruin to build and operate next-generation, sports, and entertainment direct-to-consumer streaming services. Bruin company, Deltatre, the global leader in sports media technology, provides the streaming platform technology. All marketing for OverTier on behalf of NFL Game Pass is led by Two Circles, a data-driven sports agency, with the support of Wavemaker, a full-service global media agency, both part of WPP’s GroupM.
Among the innovations to be rolled out in 2019 are:
- Watch Around The World: NFL Game Pass subscribers will be able to use their subscription in any of the 181 territories it is active
- Watch with RedZone: Thanks to new split-screen functionality, Season Pro subscribers will be able to watch NFL RedZone alongside one live game (outside of Europe).
- Smart TV and PS4 apps: NFL Game Pass is accessible on more devices, including Samsung and LG Smart TVs
- Film Sessions - Season 2: Across the 2019 season, 17 new installments of the hit series NFL Game Pass: Film Sessions will be available exclusively to NFL Game Pass International subscribers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005597/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 06:00:00 CEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom